How Does a Clinical Trial Affect Your Medical Device Insurance Program?

A clinical trial adds an exposure your standard device program was not built to cover. Product liability answers harm from a commercial product. A trial is an investigational activity: a device that is not cleared, used on enrolled subjects under a protocol, with consent and oversight obligations attached. Most device companies assume their existing program extends to trial work. It usually does not, and the gap sits exactly where the human exposure is highest.

A Trial Is a Different Risk Than a Product

When a device is in a trial, it is being studied, not sold. The subjects are enrolled under a protocol, they consent to an investigational procedure, and an institutional review board oversees the study. The liability that flows from that setting is about the conduct of the trial: injury to a subject, a consent or protocol failure, or an oversight lapse. A standard products liability policy responds to bodily injury from a defect in a product placed on the market, and the wording often assumes a commercial product rather than an investigational one. The two are not the same exposure, and a policy scoped for the commercial setting can leave the trial setting unanswered.

This matters most during an IDE study or a pivotal trial, where subjects are exposed to a device whose safety profile is precisely what the study exists to establish. That is the moment a company most needs coverage built for human-subject research, and it is the moment a commercial product policy is least likely to apply. A CRO running the study carries its own blend of exposures, covered in what insurance a contract research organization needs.

What Clinical Trial Coverage Does

Clinical trial liability coverage, carried on the sponsor side, is written for the study itself. It responds to claims of injury to enrolled subjects arising from participation, and it is structured to align with the protocol, the consent framework, and the IRB requirements that govern the trial. In many jurisdictions outside the US, evidence of trial insurance is a condition of approval to run the study at all, so the coverage is not only a risk decision but a regulatory one. The mechanics of a sponsor-side study policy, and how it coordinates with a contract research organization, sit in clinical trial coverage for sponsors and CROs.

The coverage is also time-bounded to the study in a way commercial product coverage is not. It needs to be in force for the enrollment and follow-up period, in every geography where subjects are enrolled, with limits that reflect the number of subjects and the risk of the procedure rather than the company’s revenue. International trials add jurisdictional and authorization requirements a US-only CTL was not built to answer, covered in what insurance a life sciences company needs for a clinical trial outside the US.

Mind the Seam Between Trial and Commercial

The hardest part is not the trial policy itself. It is the seam between the trial and the commercial program. When a device moves from investigation to market, product liability has to attach at first commercial shipment, and its retroactive date has to align with the end of the trial coverage so no period of exposure falls between the two. A gap at that seam is one of the most common findings in diligence, because the company is focused on the launch and not on the coverage handoff behind it. What changes at the moment of clearance is covered in how FDA clearance changes your insurance program. The discipline of getting product liability in place before clearance is the same discipline that closes this seam.

Two practical points follow. First, the trial coverage and the eventual product coverage should be planned together, not bought years apart by different people, so the dates and scopes line up by design. Second, a device that keeps generating data and software updates after launch carries a continuing exposure that the original trial never contemplated, which is its own reason to revisit the program as the product matures rather than treating clearance as the finish line.

There is a funding-stage dimension too. Pre-commercial companies running active studies sometimes defer coverage on the theory that exposure is limited before there is revenue. Clinical validation produces patient interaction, and patient interaction produces exposure, so the trial is precisely when the coverage has to exist. Deferring it does not shrink the risk; it just leaves it uninsured during the period the company can least afford a claim.

Before your next study opens, confirm you carry clinical trial liability scoped to the protocol and the geographies you will enroll in, and confirm a plan for product liability to attach cleanly when the device commercializes. A specialty review through Tower Street Insurance can structure the trial and product coverage together so neither the study nor the launch is left exposed.